Clinical Trial Update: Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST) [Phase 4]

View source ↗

Summary

Post-marketing Phase 4 study update evaluating postoperative adjuvant therapy with imatinib mesylate in patients with gastrointestinal stromal tumors (GIST).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumors

Drugs mentioned

• Imatinib mesylate (Imatinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Gastrointestinal Stromal Tumors | Phase 4 | Status: COMPLETED